Pancreatic ductal adenocarcinoma is one of the most aggressive solid tumours of the pancreas, characterised by a five-year survival rate less than 8%. Recent reports that pancreatic cancer stem cells (PCSCs) contribute to the tumorigenesis, progression, and chemoresistance of pancreatic cancer have prompted the investigation of new therapeutic approaches able to directly target PCSCs. In the present paper the non-cancer related drugs that have been proposed to target CSCs that could potentially combat pancreatic cancer are reviewed and evaluated. The role of some pathways and deregulated proteins in PCSCs as new therapeutic targets are also discussed with a focus on selected specific inhibitors. Finally, advances in the development of nanoparticles for targeting PCSCs and site-specific drug delivery are highlighted, and their limitations considered. Core tip: Pancreatic cancer is characterised by remarkable resistance to treatment conferred by pancreatic cancer stem cells (PCSCs). Unfortunately, most conventional treatments are unable to eradicate tumours. Recent research has focused on characterising PCSCs to accelerate the development of novel therapeutic strategies. In the present paper, we shed light on promising new strategies such as using non-cancer drugs as anticancer therapeutics, targeting of deregulated pathways and proteins of PCSCs, and using nanoparticles for improved drug delivery. Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma.
INTRODUCTION
Pancreatic cancer comprises many types of cancers, of which the most common is an infiltrating neoplasm named pancreatic ductal adenocarcinoma (PDAC) [1] , which derives from the pancreatic ductal tree [2] . PDAC is almost always fatal, it is refractory to conventio nal treatments, and consequently has a documented fiveyear survival rate as low as 8%. The major driver genes participating in the whole process of disease development include KRAS, TP53, CDKN2A, and SMAD4. With a near 100% KRAS mutation frequency, PDAC is considered the most RASaddicted of all cancers [3] . PDAC is also characterised by a dense tumour microen vironment, perineural and vascular local growth, and early distant metastases. In particular, it typically has a tendency to metastasise preferentially to the liver where soluble factors and extracellular vesicles deriving from the primary tumour contribute to form a supportive niche [4] . Patients seldom exhibit symptoms. Therefore, early diagnosis of the tumour is very difficult. Indeed, the majority of patients are diagnosed when metastatic events have occurred or during advancedstage disease. For this reason, primary prevention such as avoiding smoking and having a fatpoor diet is important [5] . Curr ently, surgery coupled with chemo or radiation therapy is the main treatment approach although it doesn't present satisfactory results [6] . Moreover, disease can persist or recur with local and distant metastases. Most patients subjected to resection of the tumour die from metastasis within five years [7] . Despite its low efficacy, gemcitabine (a pyrimidine analogue) was the firstchoice chemotherapeutic strategy in advanced PDAC for many years [8] . It is effective in only 23.8% of PDAC cases [9] due to dense tumour stroma and scarce diffusion of drug and to subsequent development of gemcitabine chemoresistance [10] . Recently, understanding of pancreatic carcinogenesis has improved and some new therapeutic options have been suggested. For example, it has been demonstrated that FOLFIRINOX, a chemotherapy regimen made up of four drugs (folinic acid, 5fluorouracil, irinotecan, and oxaliplatin), or nabpaclitaxel plus gemcitabine provide a survival benefit over gemcitabine alone [11] . However, we are still far from a substantially better life expectancy for patients since these new therapeutic options increase the median survival by only a few months.
A growing body of evidence suggests that the drug resistance and metastasis of PDAC are mainly influenced by the presence of cancer stem cells (CSCs). In the present paper, we aim to summarise the current understanding of pancreatic cancer stem cells (PCSCs) 
PCSCs

PCSCs characteristics
It has recently been demonstrated that CSCs play critical roles in resistance to anticancer treatment and are responsible for metastasis in several human mali gnancies, including PDAC [12] . CSCs are rare immortal tumour cells, which have the ability to selfrenew, pro duce differentiated progeny, form tumours in mice, and form nonadherent spheroids called tumourspheres in vitro [13, 14] . CSCs are more resistant than nonCSCs to che motherapy and radiotherapy treatments because they have higher expression levels of antiapoptotic proteins, ABC transporters, and multidrug resistance genes [15] . These cells reside in a niche, a specific hypoxic/necrotic microenvironment that includes different cell types (each one possessing distinct metabolic properties), such as fibroblastic, immune, endothelial, and perivascular cells, as well as extracellular matrix components, cytokines, and growth factors. In this environment, CSCs protect and reprogramme their metabolism and respond to the metabolism of surrounding cells, increasing tumour gro wth and preserving phenotypic plasticity [14, 16] . Induction and maintenance of CSC phenotypes are related to more than 20 different transcription factors, including NFκB and the hypoxia inducible factors [13, 17] . Moreover, CSCs adjust their metabolism to their microenvironm ent by acquiring intermediate metabolic phenotypes or shifting from oxidative phosphorylation (OXPHOS) to gly colysis/Warburg effect. CSCs are also characterised by a high autophagic flux, which is involved in resistance to microenvironment stresses, such as hypoxia, starvation, or anticancer treatment [18] . Thus, it has been supposed that autophagy plays a significant role in the resistance to CSCs related anticancer therapy [19] . Pancreatic CSCs, first described in 2007 [20] , represent less than 1% of all pancreatic cancer cells [21] and are responsible for PDAC tumour growth (initiation, prog ression, and recurrence), maintenance, metastasis, and chemoresistance. The origin of PCSCs remains unknown. The hypothesized sources are: Tissue stem cells or progenitor cells, stem cells derived from bone marrow, or dedifferentiated cells that result from gen etic mutation [22] . PCSCs can be identified by markers, such as CD133, CD24, CD44, ESA/EpCAM (epithelialspe cific antigen), cMet, ALDH1, DclK1, CXCR4, and Lgr5. However, a universal signature is still lacking [13, 23, 24] . The main signalling pathways of PCSCs, which are essen tial for selfrenewal, are the epithelial to mesenchymal transition (EMT) process, and resistance to conventio nal therapies include Wnt/βcatenin, Sonic Hedgehog (SHH), and Notch. In addition, other biological aspects, such as autophagy, forkhead box protein M1 (FoxM1), mammalian target of rapamycin (mTOR), Bmi1, NODAL/ ACTIVIN, NFκB and PTEN pathways, have been shown to be implicated in PCSC activity.
Importantly, PCSCs coexist with other cellular and noncellular components that constitute the tu mour microenvironment (including cancerassociated fibroblasts, pancreatic stellate cells, and tumourasso ciated macrophages). Understanding the relationship between PCSCs and all these components is extrem ely important to improve the knowledge of the PCSC biology [12] . Recently, it has been demonstrated that PCSCs are involved in highly dynamic crosstalk with the PDAC parenchymal cells [25] by a symbiotic relationship that underlies the initiation and maintenance of early PDAC infiltration and metastasis. In particular, the se cretome of PCSCs paracrinically inhibits parental cell growth and autocrinically stimulates their own growth and vascularity, while the secretome of parental cells both paracrinically inhibits PCSC growth and autocri nically inhibits their own growth. It is clear that to make a substantial impact on pancreatic cancer, it is necessary to eradicate PCSCs with targeted therapeutics [26] . For this reason, a complete molecular characterisation of PCSC biology is fundamental. Recently, we have chara cterised the proteome [7] and the secretome [27] of Panc1
CSCs, demonstrating the functional role of fatty acid synthesis and mevalonate pathways in PCSC viability and identifying secreted proteins involved in cancer differentiation, invasion, and metastasis. Through a combined proteomics and metabolomics approach we also found that Panc1 CSCs, as compared to the par ental Panc1 cells, have induced expression of proteins and metabolites involved in glycolysis, pyruvatemalate cycle, folate cycle, pentose phosphate pathway, and lipid metabolism, and reduced expression of proteins and metabolites involved in the Krebs cycle, spliceosome, and nonhomologous end joining pathway [7] .
PCSCs chemoresistance
Chemoresistance is the major obstacle to successful cancer treatment. Many drugs are not able to eliminate PDAC, which represents the primary reason for tumour recurrence and metastasis. PCSCs are very resistant and can survive conventional treatments interfering with the total eradication of a tumour [16, 23] . The mechanisms involved in the chemoresistance of CSCs include the metabolic inactivation of the drug and efflux of the drug from the cells, as well as mutation or deregulation of the drug targets [28] . In particular, an altered drug trans port activity, as an overexpression of aldehyde dehydro genase and proteasome, and a decreased expression of the human equilibrative nucleoside transporters (ENTs) and human concentrative nucleoside transporters (CNTs), play a key role in the chemoresistance of PCSCs [23] .
As previously reported, PCSCs reside in niches that are responsible for the protection of cancer cells, tumour growth, and phenotypic plasticity. Critical components for the everchanging tumour microenvironment and for construction of CSCs niche are Wnt/RSPO (Rspondin), cJun Nterminal protein kinase (JNK), Nodal/Activin, Notch, or Hedgehog proteins [23] . This specific CSCs mi croenvironment has also been proposed to contribute to drug resistance.
Chemoresistance is also related to the EMT process, which has a fundamental role in invasive and metastatic behaviour in PDAC. EMT, in pancreatic cancer cells, is controlled by several transcription factors, such as Zeb1, which suppresses the adhesion molecule Ecadherin by repressing the miR203 (an inhibitor of stemness) and the miR200 family members (which regulate ex pression of stem cell factors) [29] . Accordingly, it has been demonstrated that the class Ⅰ HDAC inhibitor mocetinostat interferes with Zeb1 function, represses EMT, and restores the drug sensitivity of PDAC cells [30] .
In particular, EMT contributes to enhanced resistance to gemcitabine because it leads to an increase in cancer cells with reduced expression of nucleoside transpor ters (ENT and CNT) that are involved in drug uptake [31] . Finally, it has been hypothesised that quiescence prot ects PCSCs from chemotherapeutic treatment, which usually targets rapidly proliferating cells.
POTENTIAL THERAPIES TARGETING PCSCs
It is broadly accepted that development of anticancer drugs to target determinant pathways and proteins of PCSCs will improve chemotherapeutic outcomes [15] . Eradication of these CSCs should be able to stop tumour progression and reduce future tumour insurgences [26, 32] . Potential strategies to target PCSCs are discussed in the next section.
Non-cancer related drugs
Some noncancer related drugs that show anticancer effects against different human CSCs could also repre sent an option in PCSCs (Table 1) . They act through different mechanisms of action including the inhibition of some important PCSCs pathways (Figure 1) .
Antibiotics are among the molecules that exhibit extraordinarily diverse biological activities. For exam ple, salinomycin, an antibacterial and coccidiostat ionophore drug, interferes with the activity of KRAS 4B, Wnt, and EMT pathways reducing the viability of breast CSCs [33] . Interestingly, it has also been de monstrated that salinomycin blocks tumour growth and the metastatic spread of PDAC in a genetically engineered mouse model [34] . In addition, the FDA approved antibiotic azithromycin, which binds to the 50S subunit of the bacterial ribosome, inhibits tumour sphere formation in PDAC and other cancers [35] . Also, the antibiotic tigecycline, developed in response to the antibiotic resistance of some bacteria, reduces the sphere formation of CSCs in pancreatic, breast, lung, and prostate cancers [29] . In particular, it eliminates the therapyresistant chronic myeloid leukaemia CSCs [36] , and a phase Ⅰ clinical trial demonstrated the safety of its intravenous infusions in patients with acute myeloid leukaemia [37] , supporting its transfer to clinical use. Moreover, it has been demonstrated that the antibiotic nigericin increases Ecadherin expression and inhibits the EMT process of CSCs leading to a reduction of invasion and metastasis of colorectal cancer [38] . This observation suggests that it should be further investiga ted to determine whether if it is also effective for targeting PCSCs.
Some antimalarial agents may have the potential to target PCSCs. For example, it has been demonstrated that chloroquine has significant effects on PCSCs by inhibiting CXCR4 and Hedgehog pathways [39] . The same can also be said for another antimalarial compound atovaquone, which acts as a potent and selective OXPHOS inhibitor, inhibiting the sphereformation of CSCs in breast cancer [40] .
Also showing promise for targeting PCSCs is apre pitant, an FDAapproved antiemetic drug that inhibits Wnt signalling, sphere formation, growth, and stemness of CSCs in colon cancer [41] . Ketamine, a drug used as an anaesthetic and depression, reduces CSCs traits and tumour growth in a colorectal cancer model. In particular, it acts by decreasing Wnt activity [42] . Notably, ketamine reportedly inhibits the proliferation of PDAC cells [43] . Salicylic acid, also known as aspirin, is another noncancer related drug that may be a candidate for eliminating PCSCs in the successful treatment of PDAC. Indeed, aspirin, commonly used as an antipyretic and antiinflammatory drug, counteracts PCSCs features such as ALDH1 activity, NFκB signalling, selfrenewal potential, and gemcitabine resistance [44] . A phase Ⅲ trial confirmed the beneficial effect of aspirin as an adjuvant treatment to prevent disease recurrence and contribute to survival after primary therapy in breast, colorectal, gastrooesophageal, and prostate tumours [45] . Metformin, a dimethylbiguanide used as an anti diabetic drug, is also able to counteract the features of PCSCs. It inhibits the mTOR and PI3K/Akt pathways, reducing the expression of PCSCs markers in pancre atic tissue, as well as the size and number of tumour spheres. Moreover, in vivo experiments demonstrated that metformin prevents progression and metastasis in PDAC [46] . Unfortunately, a phase Ⅱ trial showed that metformin does not improve the outcome in patients with advanced metastatic PDAC treated with standard therapy [47, 48] . These findings suggest that future rese arch should include studies of more potent biguanides.
Another noncancer related drug is disulfiram, a drug widely used to control alcoholism, which is involved in the inhibition of NFκB, ERK and proteasome pathways in PDAC. It has been demonstrated that disulfiram in combination with chemotherapy or chemoradiation, is able to target PCSCs [4952] . Notably, a phase IIb trial demonstrated that the addition of disulfiram to chemo therapy prolonged survival in patients with newly dia gnosed nonsmall cell lung cancer [53] . Moreover, we have recently demonstrated [7] that atorvastatin, a drug used to lower blood cholesterol, reduces the viability of PCSCs. Accordingly, the anti cancer effect of cholesterolreducing agents has been demonstrated against other CSCs. To date, in a clinical setting statin intake was significantly associated with longer recurrencefree survival in hepatocellular carcin oma patients with hepatectomy [54] . Taken together, these findings indicate that repur posing established compounds to target PCSCs could represent a good strategy for combating PDAC. It is also economically advantageous and assures rapid translation into clinical because these compounds often are already approved by the FDA and show minor side effects compared to traditional chemotherapeutic drugs [29] .
Compounds focused on deregulated pathways and proteins
In the last ten years, many agents that target specific deranged pathways of pancreatic tumour cells have shown promise in preclinical studies. Accordingly, potenti al therapies targeting PCSCs could be developed based on their deregulated pathways and/or proteins ( Table  2) . As stated above, multiple signalling pathways are known to be important for stemness, including the Wnt/βcatenin, SHH, Notch, and mTOR pathways. Some compounds that inhibit the Wnt signalling pathway have been reported in the previous section on non cancer related drugs (i.e., salinomycin, aprepitant, and ketamine). It has been demonstrated that crocetinic acid (a carotenoid obtained from saffron) is able to target PCSCs by inhibiting the expression of both SHH and smoothened proteins, which play a key role in the SHH pathways [55] . SHH and smoothened proteins lead to the activation of the Gli transcription factor and target genes involved in stem cell maintenance. In particular, crocetinic acid decreases the number and size of the spheroids in a dosedependent manner and supresses the expression of DclK1, a PCSCs surface marker [55] . Another natural compound that inhibits the SHH pathways is sanguinarine (an isoquinoline alkaloid derived from Sanguinaria canadensis). It has been recently reported to be an effective agent for the inhi bition of PCSCs [56] . It inhibits the selfrenewal capacity of PCSCs, as well as their migration, invasion, and EMT by suppressing the SHH pathway. Recently, PCSCs have been efficiently eliminated by targeting the SHH pathway using the Gli inhibitor GANT61 in combination with rapamycin (an mTOR inhibitor) [57] . Another deregulated PCSCs pathway that can be targeted is Notch signalling. Its inhibition by γsecre tase inhibitor (RO4929097) as well as by Hes1 shRNA reduces the formation of tumourspheres and the pro portion of PCSCs [58] . Notch signalling can reportedly be inhibited by using quinomycin A (an antibiotic and also classifiable as a noncancer related drug). Quinomycin A suppresses PCSCs by reducing Notch 14 receptors and by decreasing the expression of their ligands (Jagged1, Jagged2, DLL1, DLL3, and DLL4) of the downstream protein Hes1 and the γsecretase complex [59] . Quino mycin A also decreases the expression of DclK1, CD44, CD24, and EPCAM, retarding the tumoursphere for mation of PCSCs [59] . Clinical trials published several decades ago and not related to pancreatic cancer indi cated a modest activity of quinomycin A against some tumours.
Inhibition of mTOR signalling has also been propos ed as a novel strategy for targeting CSCs. In particular, it has been shown that greater suppression of PCSCs is obtained by combining gemcitabine with the mTOR inhibitor rapamycin [60] or cMet/RON inhibitor with the mTOR inhibitor AZD8055 [61] . Changes in the expression of PCSC proteins may represent a good starting point to investigate potential therapeutic targets. Recently, we indicated that fatty acid synthase (FASN) might represent a means of era dicating PCSCs [7] . Treatment with cerulenin, a specific FASN inhibitor, led to a reduction of Panc1 CSCs viability and decreased the formation of spheroids. Accordingly, it has been demonstrated that FASN plays a pivotal role in the maintenance of stemness in other CSCs [62] .
Among the potential PCSCs targets we identified an nexin A1 (AnxA1) [7] , which is an important player in the development and progression of different types of cancer, including pancreatic cancer, and plays a role in the maintenance of stemness and drug resistance in some CSCs [63] . Recent studies have shown that knock down of AnxA1 decreases cell invasion and metastatic potential in several types of cancer, including PDAC [64] . Another potential therapeutic target that is both overexpressed and oversecreted by Panc1 CSCs and that should be investigated to reduce the viability of PCSCs is myristoylated alaninerich Ckinase substrate (MARCKS) [7, 27] , a protein involved in cell motility, cell shape, cell cycle regulation, secretion, and transmem brane transport [65] . It has been demonstrated that a peptide (MANS peptide) that inhibits the function of MARCKS reduces lung cancer metastasis [66] . Another protein overexpressed and oversecreted in Panc1 CSCs is galectin3 (Gal3) [7, 27] , which activates RAS signalling [67] . Many studies reported that Gal3 is impli cated in cancer stemness, in particular by activation of Notch signalling [68] , and that it may therefore represent a good therapeutic target [69] . Accordingly, it has been shown that downregulation of Gal3 by an allosteric inhibitor, i.e., the polysaccharide RN1 (purified from the flower of Panax notoginseng), increases metastatic can cer cell apoptosis and decreases pancreatic cancer cell growth [70, 71] .
Another potential target of PCSCs we identified was pyruvate kinase isozyme M1/M2 (PKM1/PKM2) [7] . Al though PKM2 is a key mediator of glycolysis in cancer cells, research focused on exploiting metabolic pathways for cancer therapy is still scarce. To date, antitumour effects have been demonstrated in melanoma cells following treatment with lapachol (a specific PKM2 inhibi tor) [72] , and inhibition of stemness has been reported in breast CSCs treated with diallyl disulphide which targets PKM2 (and also CD44 and AMPK signalling) [73] .
Recently a new series of small molecule PKM2 inhibitors able to inhibit the growth of tumour cells has been synthesised [74] . It could be worthwhile to evaluate their efficacy also on PCSCs.
Another protein involved in metabolism that is ove rexpressed and oversecreted by Panc1 CSCs is lacta te dehydrogenase A (LHDA) [7, 27] . LDHA is an important supporter of glucose metabolism in cancer cells. It generates adequate extracellular lactate to provide a favourable microenvironment for CSCs growth and invasion [75] . Although inhibition of LDHA activity has been proposed as an approach to cancer therapy [76] , a limited number of LDHA inhibitors are reported in the literature [77] . However, LDHA is transcriptionally regulated by the oncogenic transcription factor FoxM1 [78] , and so me FoxM1 inhibitors (such as thiostrepton, troglitazone, and the FDI6 molecule) have been reported that could indirectly lead to a reduction of LDHA [79] . Among the upstream regulators of deranged PCSCs proteins, we found there is the oestrogenrelated re ceptor gamma (ERRγ) [7] , which promotes metabolic reprogramming in CSCs, pluripotency, OXPHOS, and the glycolysis pathway [80] . A novel strategy for targeting PCSCs could be represented by the inverse agonists of ERRγ, which decrease OXPHOS and mitochondrial activity and promote apoptosis [81] . Accordingly, it has been demonstrated that GSK5182 (an inverse ago nist of ERRγ) determines the upregulation of p21 and p27, promotes G1 phase arrest, and leads to ROS accumulation and pluripotency inhibition in iPS cells [8284] .
Nanoparticles for improved drug delivery
Surgery, chemotherapy, and radiotherapy are the most common anticancer therapeutic approaches; however, the nonspecific targeting of cancer cells has made these approaches often noneffective with the consequence that higher doses of drugs need to be administered to reach the tumour region [85] . In order to improve the delivery of the drug, nanoparticles (NPs) have been developed to specifically and effectively target CSCs, reducing cytotoxicity and increasing the efficacy of treatments [86] . The different types of NPs include polymeric, magnetic, gold, and mesoporous sili ca NPs, and they provide a wide range of applications such as cancer therapy, tumour destruction through heating (hyperthermia), and drug/gene delivery [87, 88] . In particular, for targeted drug delivery NPs comprise materials such as liposomes (100400 nm), nanosph eres (1100 nm), micelles (10100 nm), nanocapsules (101000 nm) and dendrimers (320 nm) (Figure 2A ). These nanocarriers enhance the solubility and formu lation of hydrophobic or waterinsoluble drugs and con trol the drug delivery at the cancer tissue.
Some NPs have been developed to target pancre atic cancer, and liposomal formulations have gained regulatory approval [89] . The first clinical trial of NPs conducted in PDAC patients was done using a PEGylated colloidal goldrhTNF nanomedicin, termed CYT6091, which demonstrated that NPs greatly reduce the toxici ty of chemotherapeutics and may target tumours [88] . In particular, some NPs have been developed to specifi cally target PCSCs ( Figure 2B ). PDAC is characterised by dense stroma with a high amount of hyaluronic acid (HA), which reduces drug delivery and interacts with CD44 surface marker regulating the invasion of PDAC cells. HAbased nanogeldrug conjugates with enhanced anticancer activity have been designed for the target ing of CD44positive and drugresistant tumours. These conjugates are based on membranotropic cholesteryl HA (CHA) with various encapsulated drugs, such as the noncancer related drug salinomycin, etoposide (a chemotherapeutic agent), or curcumin (a natural compound), and all have higher cytotoxicity in CD44 expressing drugresistant PDAC cells compared to free drugs and to nonmodified HAdrug conjugates [90] . Re cently, HAmodified poly (dllacticcoglycolic acid) poly (ethylene glycol) (HAPLGAPEG) NPs have been developed for targeted delivery of TTQ (thiotetrazo lyl analogue of a clinical candidate, IC87114) to CD44 overexpressing cancer cells. In vitro results showed that cellular uptake led to higher cytotoxicity and en hanced intracellular accumulation of these NPs in high expressing CD44 MiaPaCa2 cells [91] . Natural productbased compounds can be an attra ctive strategy for the treatment of pancreatic cancer and could be integrated with NP approaches. For some of these, an inhibiting action against PCSCs has already been demonstrated (for example resveratrol, quercetin, and green tea catechins, and curcumin) [92] , and for this reason they would deserve to be analysed as nanoparticle formulations. Among these natural compounds there are withaferin A (a major component of Withania somnifora) and carnosol (found in Rosmarinus officinalis, Salvia carnosa, and Origanum vulgare). They have suppressive effects on the proliferation, migration, and activation of cMet in PCSCs [93] . A recent study investigated the role of αmangostin (derived from the plant mangos teen) encapsulated NPs (MangNPs) in the inhibition of pancreatic carcinogenesis by targeting CSCs in human and transgenic mice. The data obtained indicated that MangNPs suppress PCSCs features (i.e., EMT, cell proliferation, cell cycle, pluripotency, selfrenewal, and apoptosis) and also target CSCs in mice [94] . A similar ap proach has been implemented for the investigation of the efficacy of anthothecol (an antimalarial compound) encapsulated by PLGA NPs (anthoNPs) against PCSCs. Interestingly, it has been demonstrated that anthoNPs specifically inhibit PCSCs growth by modulating the SHH pathway [95] . Although significant progress has been made in the development of NPs, they are far from optimal. Indeed, there are already problems regarding the low drug loading capacity of some NPs. Liposomes are sometimes affected by drug diffusion through the liposome bilayer, and micellar drugs exhibit in vivo instability [90] . For these reasons, polymeric and nanogel drug conjugates, characterized by controlled drug release and higher drug loading capacity, provide a better strategy. Other challenges that must be addressed in the future for clinical use of NPs concern inefficient delivery, inher ent toxicity, offtarget effects, unfavourable biological distribution, and lack of clearance from the systemic circulation [96] . In conclusion, even if further research is needed for the development of efficient NPs, it is possible to speculate that the targeted delivery sys tem for anticancer agents will be translated into clini cal practice. It is tempting to imagine that in the near future modified NPs might serve as promising nanocar riers for sitespecific drug delivery by targeting PCSCs and that protocol might be further improved for in vivo applications.
CONCLUSION
In conclusion, although further studies are needed, the new developments in targeting PCSCs are expected to have high impact in the treatment of PDAC in coming years. Nevertheless, some questions still need furth er investigation. While PCSCs represent an intriguing target for therapy, their complete characterisation is still needed. The identification of proteomic profiles and in particular of the deregulated pathways and proteins of PCSCs is fundamental to increasing our knowledge about pancreatic cancer and to identify new therapeutic approaches to eradicate PDAC stem cells that result in recurrence of the disease. Thus, enhanced biological knowledge of PCSCs, combined with the development of nanoparticle technology, promises to be key for the development of new effective treatments of pancreatic cancer.
